Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effect on Glucose Variability Post Bariatric Surgery
NCT07515391Phase 2Enrolling by invitation
- Sponsor
- Dasman Diabetes Institute
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in glycemic variability (GV), type 2 diabetes mellitus (T2DM), sponsored by Dasman Diabetes Institute. Started Oct 2019; status: enrolling by invitation.
02
Drugs
dapagliflozin
03
Conditions
glycemic variability (GV)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07515391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515391.